Last 12 months
Inside the activity.
0 purchase rows · 457 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 47 |
| Dec 2025 | 0 | 21 |
| Jan 2026 | 0 | 41 |
| Feb 2026 | 0 | 21 |
| Mar 2026 | 0 | 54 |
| Apr 2026 | 0 | 29 |
| May 2026 | 0 | 33 |
| Jun 2026 | 0 | 68 |
| Jul 2026 | 0 | 47 |
| Aug 2026 | 0 | 33 |
| Sep 2026 | 0 | 59 |
| Oct 2026 | 0 | 4 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 20, 2026 Filed Jan 23, 2026 02:05 UTC |
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
|
SaleCommon Stock | 23,205 | $234.74 | $5,447,104.57 |
DisclosureSEC source: 0002010019-26-000004 · form4-01222026_090103.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,992 F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units (RSUs) and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:35 UTC |
Chapman Steven LeonardDirector · CEO AND PRESIDENT
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001711968-26-000004 · form4-01222026_090103.xml · derivative · entry 4 Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,386 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest over four years. 25% of the RSUs vested on January 20, 2023 and the remaining shares vest in 12 equal quarterly installments thereafter. F4 · derivative.expiration_date: The RSUs vest over four years. 25% of the RSUs vested on January 20, 2023 and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:35 UTC |
Chapman Steven LeonardDirector · CEO AND PRESIDENT
|
Exercise / conversionCommon Stock | 3,386 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001711968-26-000004 · form4-01222026_090103.xml · nonDerivative · entry 2 Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 220,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:35 UTC |
Chapman Steven LeonardDirector · CEO AND PRESIDENT
|
SaleCommon Stock | 71,932 | $234.74 | $16,885,202.59 |
DisclosureSEC source: 0001711968-26-000004 · form4-01222026_090103.xml · nonDerivative · entry 1 Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 217,354 F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units (RSUs) and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:35 UTC |
Brophy Michael BurkesCHIEF FINANCIAL OFFICER
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,522 | $0.00 | $0.00 |
DisclosureSEC source: 0001697362-26-000002 · form4-01222026_090101.xml · derivative · entry 5 Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,522 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vest over four years. 25% of the RSUs vested on January 20, 2023 and the remaining shares vest in 12 equal quarterly installments thereafter. F5 · derivative.expiration_date: The RSUs vest over four years. 25% of the RSUs vested on January 20, 2023 and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:35 UTC |
Brophy Michael BurkesCHIEF FINANCIAL OFFICER
|
Exercise / conversionCommon Stock | 1,522 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001697362-26-000002 · form4-01222026_090101.xml · nonDerivative · entry 2 Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:35 UTC |
Brophy Michael BurkesCHIEF FINANCIAL OFFICER
|
SaleCommon Stock | 23,948 | $234.74 | $5,621,515.20 |
DisclosureSEC source: 0001697362-26-000002 · form4-01222026_090101.xml · nonDerivative · entry 1 Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,776 F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units (RSUs) and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:05 UTC |
Sheena JonathanDirector · CO-FOUNDER
|
Exercise / conversionRestricted Stock Unit · Derivative | 191 | $0.00 | $0.00 |
DisclosureSEC source: 0001646649-26-000004 · form4-01222026_090108.xml · derivative · entry 8 Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 191 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The RSUs vest over four years. 25% of the RSUs vested on January 20, 2023 and the remaining shares vest in 12 equal quarterly installments thereafter. F7 · derivative.expiration_date: The RSUs vest over four years. 25% of the RSUs vested on January 20, 2023 and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:05 UTC |
Sheena JonathanDirector · CO-FOUNDER
|
Exercise / conversionCommon Stock | 191 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001646649-26-000004 · form4-01222026_090108.xml · nonDerivative · entry 4 Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 267,241 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:05 UTC |
Sheena JonathanDirector · CO-FOUNDER
|
SaleCommon Stock | 2,981 | $234.74 | $699,755.17 |
DisclosureSEC source: 0001646649-26-000004 · form4-01222026_090108.xml · nonDerivative · entry 3 Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 267,050 F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units (RSUs) and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:05 UTC |
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICER
|
Exercise / conversionRestricted Stock Unit · Derivative | 856 | $0.00 | $0.00 |
DisclosureSEC source: 0001857843-26-000003 · form4-01222026_090105.xml · derivative · entry 4 RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 856 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest over four years. 25% of the RSUs vested on January 20, 2023 and the remaining shares vest in 12 equal quarterly installments thereafter. F4 · derivative.expiration_date: The RSUs vest over four years. 25% of the RSUs vested on January 20, 2023 and the remaining shares vest in 12 equal quarterly installments thereafter. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:05 UTC |
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICER
|
Exercise / conversionCommon Stock | 856 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001857843-26-000003 · form4-01222026_090105.xml · nonDerivative · entry 2 RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 227,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 02:05 UTC |
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICER
|
SaleCommon Stock | 19,234 | $234.74 | $4,514,958.39 |
DisclosureSEC source: 0001857843-26-000003 · form4-01222026_090105.xml · nonDerivative · entry 1 RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 226,615 F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units (RSUs) and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 27, 2023. Read SEC document |
| January 14, 2026 Filed Jan 17, 2026 02:05 UTC |
Fesko JohnPRESIDENT, CHIEF BUS. OFFICER
|
GrantCommon Stock | 44,698 | $0.00 | $0.00 |
DisclosureSEC source: 0002010135-26-000001 · form4-01162026_090107.xml · nonDerivative · entry 1 Fesko John · CIK 0002010135 · PRESIDENT, CHIEF BUS. OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 195,397 F1 · shares: On January 27, 2023, the Reporting Person was granted a performance-based Restricted Stock Unit (RSU) award which vests in tranches upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 14, 2026, the performance threshold with respect to one milestone under the RSUs was certified, resulting in the vesting of 44,698 shares of Common Stock. Read SEC document |
| January 14, 2026 Filed Jan 17, 2026 02:05 UTC |
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
|
GrantCommon Stock | 44,698 | $0.00 | $0.00 |
DisclosureSEC source: 0002010019-26-000003 · form4-01162026_090105.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,197 F1 · shares: On January 27, 2023, the Reporting Person was granted a performance-based Restricted Stock Unit (RSU) award which vests in tranches upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 14, 2026, the performance threshold with respect to one milestone under the RSUs was certified, resulting in the vesting of 44,698 shares of Common Stock. Read SEC document |
| January 14, 2026 Filed Jan 17, 2026 02:05 UTC |
Chapman Steven LeonardDirector · CEO AND PRESIDENT
|
GrantCommon Stock | 152,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001711968-26-000003 · form4-01162026_090109.xml · nonDerivative · entry 1 Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 289,286 F1 · shares: On January 27, 2023, the Reporting Person was granted a performance-based Restricted Stock Unit (RSU) award which vests in tranches upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 14, 2026, the performance threshold with respect to one milestone under the RSUs was certified, resulting in the vesting of 152,718 shares of Common Stock. Read SEC document |
| January 14, 2026 Filed Jan 17, 2026 02:05 UTC |
Brophy Michael BurkesCHIEF FINANCIAL OFFICER
|
GrantCommon Stock | 59,596 | $0.00 | $0.00 |
DisclosureSEC source: 0001697362-26-000001 · form4-01162026_090111.xml · nonDerivative · entry 1 Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,722 F1 · shares: On January 27, 2023, the Reporting Person was granted a performance-based Restricted Stock Unit (RSU) award which vests in tranches upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 14, 2026, the performance threshold with respect to one milestone under the RSUs was certified, resulting in the vesting of 59,596 shares of Common Stock. Read SEC document |
| January 14, 2026 Filed Jan 17, 2026 02:05 UTC |
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICER
|
GrantCommon Stock | 37,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001857843-26-000002 · form4-01162026_090103.xml · nonDerivative · entry 1 RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 245,849 F1 · shares: On January 27, 2023, the Reporting Person was granted a performance-based Restricted Stock Unit (RSU) award which vests in tranches upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 14, 2026, the performance threshold with respect to one milestone under the RSUs was certified, resulting in the vesting of 37,248 shares of Common Stock. Read SEC document |
| January 14, 2026 Filed Jan 17, 2026 02:05 UTC |
Sheena JonathanDirector · CO-FOUNDER
|
GrantCommon Stock | 7,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001646649-26-000003 · form4-01162026_090101.xml · nonDerivative · entry 1 Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 270,031 F1 · shares: On January 27, 2023, the Reporting Person was granted a performance-based Restricted Stock Unit (RSU) award which vests in tranches upon the achievement of milestones relating to a combination of the passage of time and certain business performance criteria. On January 14, 2026, the performance threshold with respect to one milestone under the RSUs was certified, resulting in the vesting of 7,450 shares of Common Stock. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 02:05 UTC |
Sheena JonathanDirector · CO-FOUNDER
|
Exercise / conversionStock Option (right to buy) · Derivative | 39,615 | $0.00 Strike: $9.59 | $0.00 |
DisclosureSEC source: 0001646649-26-000002 · form4-01062026_090105.xml · derivative · entry 4 Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,615 shares Expires 2026-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option shares are fully exercisable. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 02:05 UTC |
Sheena JonathanDirector · CO-FOUNDER
|
Exercise / conversionCommon Stock | 39,615 | $9.59 | $379,907.85 |
DisclosureSEC source: 0001646649-26-000002 · form4-01062026_090105.xml · nonDerivative · entry 1 Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 02:05 UTC |
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
|
SaleCommon Stock | 1,659 | $229.43 | $380,619.89 |
DisclosureSEC source: 0002010019-26-000002 · form4-01062026_090103.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,499 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.94 to $229.73 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 02:05 UTC |
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
|
SaleCommon Stock | 1,292 | $228.33 | $295,001.58 |
DisclosureSEC source: 0002010019-26-000002 · form4-01062026_090103.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,158 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $227.8050 to $228.76 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 02:05 UTC |
Chapman Steven LeonardDirector · CEO AND PRESIDENT
|
SaleCommon Stock | 1,634 | $229.67 | $375,283.39 |
DisclosureSEC source: 0001711968-26-000002 · form4-01062026_090101.xml · nonDerivative · entry 2 Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,568 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $229.12 to $229.98 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 02:05 UTC |
Chapman Steven LeonardDirector · CEO AND PRESIDENT
|
SaleCommon Stock | 2,214 | $228.64 | $506,198.33 |
DisclosureSEC source: 0001711968-26-000002 · form4-01062026_090101.xml · nonDerivative · entry 1 Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,202 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.07 to $229.02 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 01:05 UTC |
Sheena JonathanDirector · CO-FOUNDER
|
SaleCommon Stock | 550 | $226.34 | $124,489.42 |
DisclosureSEC source: 0001646649-25-000023 · form4-12222025_081202.xml · nonDerivative · entry 5 Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER 10b5-1 filing: Plan reported Ownership: Indirect · By Caraluna 2 Trust Disclosed balance after: 22,532 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.84 to $226.64 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 01:05 UTC |
Sheena JonathanDirector · CO-FOUNDER
|
SaleCommon Stock | 200 | $224.74 | $44,948.20 |
DisclosureSEC source: 0001646649-25-000023 · form4-12222025_081202.xml · nonDerivative · entry 4 Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER 10b5-1 filing: Plan reported Ownership: Indirect · By Caraluna 2 Trust Disclosed balance after: 23,082 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.74 to $224.75 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 01:05 UTC |
Sheena JonathanDirector · CO-FOUNDER
|
SaleCommon Stock | 550 | $226.36 | $124,497.56 |
DisclosureSEC source: 0001646649-25-000023 · form4-12222025_081202.xml · nonDerivative · entry 3 Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER 10b5-1 filing: Plan reported Ownership: Indirect · By Caraluna 1 Trust Disclosed balance after: 22,532 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.84 to $226.64 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 01:05 UTC |
Sheena JonathanDirector · CO-FOUNDER
|
SaleCommon Stock | 200 | $224.89 | $44,978.60 |
DisclosureSEC source: 0001646649-25-000023 · form4-12222025_081202.xml · nonDerivative · entry 2 Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER 10b5-1 filing: Plan reported Ownership: Indirect · By Caraluna 1 Trust Disclosed balance after: 23,082 F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.74 to $225.50 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 01:35 UTC |
Sheena JonathanDirector · CO-FOUNDER
|
SaleCommon Stock | 130 | $228.28 | $29,676.80 |
DisclosureSEC source: 0001646649-25-000021 · form4-12172025_081201.xml · nonDerivative · entry 4 Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 222,966 F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $227.98 to $228.31 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 01:35 UTC |
Sheena JonathanDirector · CO-FOUNDER
|
SaleCommon Stock | 1,348 | $227.44 | $306,583.05 |
DisclosureSEC source: 0001646649-25-000021 · form4-12172025_081201.xml · nonDerivative · entry 3 Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 223,096 F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $226.96 to $227.84 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 01:35 UTC |
Sheena JonathanDirector · CO-FOUNDER
|
SaleCommon Stock | 1,592 | $226.54 | $360,652.32 |
DisclosureSEC source: 0001646649-25-000021 · form4-12172025_081201.xml · nonDerivative · entry 2 Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 224,444 F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.94 to $226.90 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 02:05 UTC |
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
|
GiftCommon Stock | 115 | $0.00 | $0.00 |
DisclosureSEC source: 0002010019-25-000016 · form4-12162025_091203.xml · nonDerivative · entry 5 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,450 F1 · shares: Represents a charitable contribution by the Reporting Person. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 01:35 UTC |
Sheena JonathanDirector · CO-FOUNDER
|
GiftCommon Stock | 1,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001646649-25-000021 · form4-12172025_081201.xml · nonDerivative · entry 1 Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 226,036 F1 · shares: Represents a charitable contribution by the Reporting Person. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:05 UTC |
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
|
Exercise / conversionCommon Stock | 13,500 | $9.59 | $129,465.00 |
DisclosureSEC source: 0002010019-25-000016 · form4-12162025_091203.xml · nonDerivative · entry 4 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:05 UTC |
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
|
SaleCommon Stock | 4,692 | $230.76 | $1,082,714.19 |
DisclosureSEC source: 0002010019-25-000016 · form4-12162025_091203.xml · nonDerivative · entry 3 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,065 F2 · shares: The sale of these shares was effected in order to cover the exercise price and satisfy tax withholding and remittance obligations in connection with the exercise of expiring options. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:05 UTC |
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
|
Exercise / conversionCommon Stock | 8,876 | $9.59 | $85,120.84 |
DisclosureSEC source: 0002010019-25-000016 · form4-12162025_091203.xml · nonDerivative · entry 2 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:05 UTC |
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
|
GiftCommon Stock | 180 | $0.00 | $0.00 |
DisclosureSEC source: 0002010019-25-000016 · form4-12162025_091203.xml · nonDerivative · entry 1 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,881 F1 · shares: Represents a charitable contribution by the Reporting Person. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:05 UTC |
ROSENMAN HERMDirector
|
SaleCommon Stock | 150 | $229.10 | $34,364.25 |
DisclosureSEC source: 0001230057-25-000005 · form4-12162025_091201.xml · nonDerivative · entry 5 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,342 Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:05 UTC |
ROSENMAN HERMDirector
|
SaleCommon Stock | 11,987 | $228.49 | $2,738,859.28 |
DisclosureSEC source: 0001230057-25-000005 · form4-12162025_091201.xml · nonDerivative · entry 4 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,492 F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.00 to $228.99 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:05 UTC |
ROSENMAN HERMDirector
|
SaleCommon Stock | 21,910 | $227.35 | $4,981,308.61 |
DisclosureSEC source: 0001230057-25-000005 · form4-12162025_091201.xml · nonDerivative · entry 3 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,479 F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $226.95 to $227.91 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 02:05 UTC |
ROSENMAN HERMDirector
|
SaleCommon Stock | 14,372 | $226.62 | $3,256,945.27 |
DisclosureSEC source: 0001230057-25-000005 · form4-12162025_091201.xml · nonDerivative · entry 2 ROSENMAN HERM · CIK 0001230057 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,389 F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.9450 to $226.9350 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2025 Filed Dec 17, 2025 02:05 UTC |
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
|
Exercise / conversionStock Option (right to buy) · Derivative | 22,376 | $0.00 Strike: $9.59 | $0.00 |
DisclosureSEC source: 0002010019-25-000016 · form4-12162025_091203.xml · derivative · entry 6 Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,125 Underlying: Common Stock · 22,376 shares Expires 2026-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The options exercised were composed of 13,500 incentive stock options and 8,876 non-qualified stock options. F4 · derivative.exercise_date: The option shares are fully exercisable. Read SEC document |
| December 09, 2025 Filed Dec 12, 2025 01:35 UTC |
Sheena JonathanDirector · CO-FOUNDER
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,436 | $0.00 Strike: $9.29 | $0.00 |
DisclosureSEC source: 0001646649-25-000019 · form4-12112025_081201.xml · derivative · entry 4 Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,544 Underlying: Common Stock · 4,436 shares Expires 2028-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option shares are fully exercisable. Read SEC document |
| December 09, 2025 Filed Dec 12, 2025 01:35 UTC |
Sheena JonathanDirector · CO-FOUNDER
|
Exercise / conversionCommon Stock | 4,436 | $9.29 | $41,210.44 |
DisclosureSEC source: 0001646649-25-000019 · form4-12112025_081201.xml · nonDerivative · entry 1 Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 10, 2025 01:35 UTC |
Chapman Rowan EDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $32.15 | $0.00 |
DisclosureSEC source: 0001786240-25-000007 · form4-12092025_081201.xml · derivative · entry 4 Chapman Rowan E · CIK 0001786240 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 4,000 shares Expires 2029-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option shares are fully exercisable. Read SEC document |
| December 05, 2025 Filed Dec 10, 2025 01:35 UTC |
Chapman Rowan EDirector
|
SaleCommon Stock | 366 | $243.39 | $89,080.74 |
DisclosureSEC source: 0001786240-25-000007 · form4-12092025_081201.xml · nonDerivative · entry 3 Chapman Rowan E · CIK 0001786240 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,777 Read SEC document |
| December 05, 2025 Filed Dec 10, 2025 01:35 UTC |
Chapman Rowan EDirector
|
SaleCommon Stock | 4,000 | $243.08 | $972,308.40 |
DisclosureSEC source: 0001786240-25-000007 · form4-12092025_081201.xml · nonDerivative · entry 2 Chapman Rowan E · CIK 0001786240 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,143 Read SEC document |
| December 05, 2025 Filed Dec 10, 2025 01:35 UTC |
Chapman Rowan EDirector
|
Exercise / conversionCommon Stock | 4,000 | $32.15 | $128,600.00 |
DisclosureSEC source: 0001786240-25-000007 · form4-12092025_081201.xml · nonDerivative · entry 1 Chapman Rowan E · CIK 0001786240 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2025 Filed Dec 9, 2025 02:55 UTC |
RABINOWITZ DANIELSEC. AND CHIEF LEGAL OFFICER
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,902 | $0.00 Strike: $19.68 | $0.00 |
DisclosureSEC source: 0001857843-25-000010 · form4-12082025_091201.xml · derivative · entry 2 RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,598 Underlying: Common Stock · 6,902 shares Expires 2029-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option shares are fully exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.